title: In vivo activity of ursolic and oleanolic acids during the acute phase of Trypanosoma cruzi infection.
abstract: Reduction in the parasitemic levels of the Y strain of Trypanosoma cruzi in mice treated with oral or intraperitoneal ursolic (UA) and oleanolic (OA) acids was evaluated during the acute phase of Chagas' disease. Oral administration of UA and OA (50mg/kg/day) provided the most significant reduction in the parasitemic peak, while intraperitoneal administration of UA and OA did not significantly affect the biological activity of the Y strain of T. cruzi. Interleukin levels in mice treated by the intraperitoneal route were compared to untreated chagasic mice. Reduced γ-IFN levels and enhanced IL-10 concentrations potentially explain the exacerbated parasitemia. Our data suggests an immunosuppressive effect for UA and OA, which could interfere with host control of parasitemia. Optimal results were achieved with oral administration. This observation may be explained by the low intestinal absorption of UA and OA, could cause a reduced immune response and promote parasite control. Taken together, these data demonstrate that triterpenes could be interesting compounds to develop therapeutically for the treatment of Chagas' disease.
authors: Universidade de Franca - Núcleo de Pesquisa em Ciências Exatas e Tecnológicas da Universidade de Franca, Av. Dr. Armando Salles Oliveira, 201, 14404-600 Franca, SP, Brazil. danieleferreira1@aluno.unifran.br
authors: Daniele
authors: D
authors: da Silva Ferreira
authors: Viviane Rodrigues
authors: VR
authors: Esperandim
authors: Miriam Paula Alonso
authors: MP
authors: Toldo
authors: Christian Collins
authors: CC
authors: Kuehn
authors: José Clóvis
authors: JC
authors: do Prado Júnior
authors: Wilson Roberto
authors: WR
authors: Cunha
authors: Márcio Luís Andrade
authors: ML
authors: e Silva
authors: Sérgio
authors: S
authors: de Albuquerque
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D014355:Chagas Disease / Q000188:drug therapy* / Q000276:immunology; D004195:Disease Models, Animal; D007263:Infusions, Parenteral; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D008297:Male; D035322:Melastomataceae / Q000737:chemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000627:therapeutic use; D009828:Oleanolic Acid / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D018512:Parasitemia / Q000188:drug therapy / Q000276:immunology; D011897:Random Allocation; D014315:Triterpenes / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D014344:Trypanocidal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000097245:Ursolic Acid
chemical_list: D000890:Anti-Infective Agents; D007371:Interferon-gamma; D016753:Interleukin-10; D009593:Nitroimidazoles; D009828:Oleanolic Acid; D014315:Triterpenes; D014344:Trypanocidal Agents; D000097245:Ursolic Acid; C009999:benzonidazole
keywords: Interleukin; Oleanolic acid; Trypanosoma cruzi; Ursolic acid